NCT04615351

Brief Summary

A Pilot of Metformin Postpartum

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Nov 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 26, 2020

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 4, 2020

Completed
11 days until next milestone

Study Start

First participant enrolled

November 15, 2020

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2021

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

November 4, 2020

Status Verified

October 1, 2020

Enrollment Period

12 months

First QC Date

October 26, 2020

Last Update Submit

October 31, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prediabetes or Diabetes

    glycosylated hemoglobin (HgbA1c) at 1 year postpartum (\>/= 5.7% defined as prediabetes, \>/=6.5% defined as DM

    1 year postpartum

Secondary Outcomes (1)

  • Prediabetes or diabetes at 15 months postpartum

    15 months after delivery and study initiation

Study Arms (2)

Metformin

ACTIVE COMPARATOR

Metformin 500 mg to be taken twice per day for two weeks and then metformin 1000 mg PO twice daily after tolerating the lower dose

Drug: Metformin

Routine Care

NO INTERVENTION

Discharge information about maintaining a healthy diet

Interventions

Medication

Metformin

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Gestational Diabetes

You may not qualify if:

  • Cannot tolerate metformin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women & Infants Hospital

Providence, Rhode Island, 02905, United States

RECRUITING

MeSH Terms

Conditions

Diabetes, Gestational

Interventions

Metformin

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Central Study Contacts

Donna Allard

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2020

First Posted

November 4, 2020

Study Start

November 15, 2020

Primary Completion

October 31, 2021

Study Completion

June 30, 2022

Last Updated

November 4, 2020

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will share

Locations